SIMPONI® 50 mg Prescribing Information Great Britain / Northern Ireland [External links]
SIMPONI® 100 mg Prescribing Information Great Britain / Northern Ireland [External links]
SIMPONI (golimumab) was developed to fit with patient needs and lifestyle, whilst continuing to improve functionality and disease outcomes. It is the first and only subcutaneous anti-TNF therapy with convenient once-monthly dosing from day one, licenced for Rheumatoid Arthritis, Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis and Psoriatic Arthritis within Rheumatology.1
SIMPONI, alone or in combination with methotrexate (MTX), is indicated for the treatment of active and progressive PsA in adult patients when response to disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.1
66% of PsA patients still responding with an ACR20 at 5 years (n=96/146)*2
Find out moreSIMPONI is indicated for the treatment of severe, active AS in adults who have responded inadequately to conventional therapy.1
66% of AS patients still responding with an ASAS20 at 5 years. (n=235/356)**3
Find out moreSIMPONI is indicated in combination with MTX to treat moderate to severe, active RA in adults when the response to DMARD therapy including MTX has been inadequate and severe, active and progressive RA in adults not previously treated with MTX.1
70% of bio-naïve RA patients still responding with ACR20 at 5 years (n=62/89)*4
42% of bio-experienced RA patients achieved an ACR20 at 5 years (n=84/201)**5
Find out moreSIMPONI is indicated to treat adults with severe, active nr-axSpA with objective signs of inflammation as indicated by elevated C reactive protein and/or MRI evidence, who have had an inadequate response to, or are intolerant to NSAIDs.1
84% of patients were still responding with an ASAS20 at week 52 (n= 78/93)*6
Find out moreACR20: ≥20% improvement in the American College of Rheumatology criteria ASAS20 ≥20% assessment of SpondyloArthritis International Society
* SIMPONI 50 mg
** SIMPONI 50 mg or 100 mg
By study design, randomisation of weight; patients in the long term extension may have switched between the 50
mg and 100 mg SIMPONI doses at the discretion of study physician.
Just one injection, once a month.1
Our patient support website will help your patients:
SIMPONI® 50 mg Prescribing Information Great Britain / Northern Ireland
SIMPONI® 100 mg Prescribing Information Great Britain / Northern Ireland
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
GB-GOL-00272 | Date of Preparation: September 2020